{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-030403","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.408943+00:00","generated_at":"2026-06-01T00:31:22.175910+00:00","sec_items":["1.01","1.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion monetizes European bempedoic acid royalties for $304.7M, pays off Oberland facility","bullets":["Received $304.7M from OMERS in exchange for 100% of European bempedoic acid royalty until OMERS receives 1.7x investment (≈$518M), then royalties revert to Esperion.","Used proceeds to early payoff and termination of Oberland Capital revenue interest facility for $343.75M cash, removing senior secured liens.","Esperion retains potential future commercial milestones from DSE of up to $300M based on net sales thresholds.","Royalty to OMERS is tiered 15-25% of DSE net sales; Esperion regains full royalty stream after cap is reached.","CFO Ben Halladay cited enhanced balance sheet and increased operational flexibility to focus on U.S. commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-030403","json":"https://secwatch.observer/filing/0001628280-24-030403.json","markdown":"https://secwatch.observer/filing/0001628280-24-030403.md","text":"https://secwatch.observer/filing/0001628280-24-030403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024030403/0001628280-24-030403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828024030403/espr-20240627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:31:22.175910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}